What Torrent Pharmaceuticals does

Torrent Pharmaceuticals Limited is an India-based, publicly listed pharmaceutical company (BSE: 500420, NSE: TORNTPHARM) founded in 1971 and headquartered in Ahmedabad, Gujarat, with FY2026 turnover of Rs 13,980 crore. The company focuses on therapeutic segments of cardiovascular, central nervous system, gastro-intestinal, diabetology, women's healthcare, vitamins/minerals/nutrients, cosmo-dermatology, pain management, gynaecology, oncology, and anti-infective. It pioneered the niche marketing concept in India and operates a 6,800+ field force reaching 2 lakh+ doctors through 27 sales divisions, supported by 5,800+ stockists and 59,000+ retailers via 23 distribution centers.

The company manufactures generic and specialty pharmaceutical formulations across 16 manufacturing plants, including USFDA-approved API and formulation facilities, an oncology plant, a dermatology-exclusive plant, and an exclusive insulin contract-manufacturing unit for Novo Nordisk at Indrad. Its R&D Centre at Bhat, Gujarat houses 999 scientists, supported by 660+ research staff overall, with proprietary drug delivery technologies including Dual Retard Inlay, Gastro Retentive System, Long Acting Injectables, Nasal Drug Delivery, and Topical Foams. The patent portfolio comprises 1,279 filings with 689 granted globally, and the US pipeline includes 120 ANDA approvals with 19 pending.

Torrent generates revenue through branded generic sales in India, international operations across 50+ countries via wholly owned subsidiaries in 14 nations (ranked #1 Indian company in Brazil and Germany, #5 overall in Germany), consumer healthcare brands (Tedibar, Shelcal, Unienzyme, Ahaglow, Prozuca), and contract manufacturing. Growth has been accelerated by acquisitions including Elder Pharma (2014), Zyg Pharma (2015), Glochem (2016), Unichem (2017), Bio-Pharm US (2018), Curatio Healthcare (2022), and J.B. Chemicals & Pharmaceuticals (Jan 2026, Rs 12,537 crore). The Mehta family holds 68.31% promoter shareholding, with Samir Mehta as Chairman and Aman Mehta as Managing Director heading India and RoW business.

Name

Torrent Pharmaceuticals

Legal name

Torrent Pharmaceuticals Ltd.

Website

https://torrentpharma.com

Company type

Public

Founded year

1971

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Torrent Pharmaceuticals is an India-based, publicly listed pharma company manufacturing generic and specialty formulations across cardiovascular, CNS, GI, diabetology, dermatology, and oncology, serving 2 lakh+ doctors in India and operating in 50+ countries, with FY2026 revenue of Rs 13,980 crore.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Specialty Care Pharmaceuticals (HLAIAAAB), Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

Keywords

• Generic pharmaceuticals
• Branded formulations
• Cardiovascular therapeutics
• Diabetes medications
• Consumer healthcare brands

Headquarters

HQ city

Ahmedabad

HQ country

India

HQ region

Asia

Offices20 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

1. Domestic Formulations (India): Sale of branded generic pharmaceutical products in India across therapeutic segments including cardiovascular, CNS, gastro-intestinal, women healthcare, vitamins/minerals/nutrients, cosmo-dermatology, diabetology, pain management, gynaecology, oncology and anti-infective. India business generated Rs 2,215 crore in Q4 FY26 with 43% YoY growth.
2. International Business: Operations across US, Europe (Germany, UK, Malta), Brazil and Rest of World markets through wholly owned subsidiaries. US business has 120 ANDAs approved with 19 in pipeline. Germany ranked #1 among Indian players and 5th in market. Brazil ranked #1 in covered market.
3. Contract Manufacturing: Exclusive formulation and packaging unit for manufacturing Insulin for Novo Nordisk since early 1990s at Indrad facility

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Torrent Pharmaceuticals manufactures and markets branded generic and generic pharmaceutical formulations across therapeutic segments including cardiovascular, central nervous system, gastro-intestinal, diabetology, women healthcare, vitamins/minerals/nutrients, cosmo-dermatology, pain management, gynaecology, oncology, and anti-infective. The company also sells consumer healthcare brands (Tedibar, Shelcal, Unienzyme, Ahaglow, Prozuca) and operates contract manufacturing for partners including Novo Nordisk.

Product overview

Torrent Pharmaceuticals operates as a leading pharmaceutical company with a diversified portfolio spanning therapeutic areas including Cardiovascular (CV), Central Nervous System (CNS), Gastro-Intestinal (GI), Diabetology, Women Healthcare (WHC), Vitamins Minerals & Nutrients (VMN), Cosmo-Dermatology, Nephrology, Oncology, and Anti-Infective segments. The company offers consumer healthcare brands (Tedibar baby care, Shelcal calcium supplements, Unienzyme digestive enzymes, Ahaglow skincare, Prozuca diabetes nutrition) alongside a comprehensive range of prescription pharmaceutical products. Major product lines include oral anti-diabetics (Azulix, Azukon, Voglitor, Piopod, Dibeta), cardiovascular medications, and weight management solutions (Orlica). Recent significant launches include generic semaglutide brands Sembolic and Semalix for diabetes and obesity treatment.

Differentiator

Problem solved

Functional benefit

Brands

• Sembolic: Oral semaglutide brand launched March 2026 for diabetes and weight management
• Semalix
• Tedibar
• Shelcal
• Unienzyme
• Ahaglow
• Prozuca
• Heumann

Products and services

• Sembolic Oral semaglutide generic formulation for diabetes and weight management, launched as the first generic oral version in India.
• Semalix Injectable semaglutide generic formulation for diabetes and weight management, launched alongside Sembolic.
• Tedibar Consumer healthcare brand for baby skincare including diaper rash cream, bathing bar, body wash, and ceramide-based moisturizing products.
• Shelcal Calcium and vitamin D3 supplement brand available in tablet, gummy, and total health formulations for bone and overall health.
• Unienzyme Digestive enzyme supplement brand with multi-enzyme formula for digestive health support.
• Ahaglow Dermatological skincare brand including face wash gel and skin repair gel with Ectoin and marine botanicals.
• Prozuca Nutritional supplement designed for individuals with diabetes to meet their nutritional needs.
• Azulix Glimepiride-based oral anti-diabetic medication available in 1-4mg strengths, also in combination with metformin (MF variants).
• Azukon Gliclazide-based oral anti-diabetic medication for type 2 diabetes management.
• Voglitor Voglibose-based alpha-glucosidase inhibitor for diabetes management, available in MD and MF formulations.
• Piopod Pioglitazone-based oral anti-diabetic agent, also available in combination formulations with glimepiride and metformin.
• Dibeta Metformin-based oral anti-diabetic medication available in sustained release (SR) formulation.
• Orlica Orlistat-based anti-obesity medication available in 60mg and 120mg tablet formulations.

Quantifiable outcome

• Q4 FY26 revenue grew 42% YoY to Rs 4,197 crore driven by JB Chemicals acquisition and strong domestic performance
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• Takeda PharmaceuticalscoreStrategic or Co-development Partner · 1 January 2024Torrent Pharmaceuticals entered into Non-Exclusive Patent Licensing Agreement with Takeda Pharmaceuticals to commercialize its novel gastrointestinal drug
• Zydus LifesciencescoreGTM or Marketing Partner · 1 January 2023Torrent and Zydus signed licensing agreement for co-marketing Saroglitazar Mg, a critical treatment for chronic liver diseases in India
• Boehringer Ingelheim IndiacoreGTM or Marketing Partner · 1 January 2022Co-marketing partnership with Boehringer Ingelheim India Private Limited to co-market its anti-diabetic drug and fixed dose combinations in India
• Dr. Reddy's LaboratoriesminorChannel Partner/ Reseller/ Distributor · 1 January 2022Acquired four brands from Dr. Reddy's - 'Styptovit-E', 'Finast', 'Finast-T', and 'Dynapress'
• Medicine Patent PoolcoreStrategic or Co-development Partner · 1 January 2022Licensing agreement with Medicine Patent Pool to manufacture and commercialize generic version of Pfizer Oral COVID-19 Treatment
• Eli Lilly (Lilly)coreStrategic or Co-development Partner · 1 January 2021Voluntary Licensing Agreement with Lilly to manufacture and distribute Baricitinib for Covid-19 treatment in India
• Merck & Co. (MSD) and Ridgeback BiotherapeuticscoreStrategic or Co-development Partner · 1 January 2021Introduced MSD and Ridgeback's molnupiravir under brand name Molnutor® in India for Covid-19 treatment
• Glenmark PharmaceuticalscoreGTM or Marketing Partner · 1 January 2019Licensing agreement for co-marketing of Remogliflozin Etabonate in India for diabetes treatment
• Reliance Life SciencesminorStrategic or Co-development Partner · 1 January 2013Licensing agreement with Reliance Life Sciences for three biosimilars - Rituximab, Adalimumab, and Cetuximab
• AstraZenecacoreStrategic or Co-development Partner · 1 January 2009License and supply agreement with AstraZeneca for marketing its products in international market. Also entered into research collaboration with AstraZeneca for developing novel anti-hypertensive drug.
• Novo NordiskcoreOEM/ Whitelabel/ Licensing Partner · 1 January 2005Torrent Pharma has been the only Indian contract manufacturer of insulin for Novo Nordisk since early 1990s, operating a dedicated formulation and packaging facility at Indrad, Gujarat. This long-standing partnership demonstrates Torrent's manufacturing excellence and regulatory compliance.

Scale indicators21 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Sun Pharmaceutical Industries: India's largest pharma company with a broad specialty and generics portfolio overlapping Torrent's CV, CNS, GI and chronic therapy focus; most direct Indian pharma comparable by scale and geographic mix.
• Cipla: Large Indian generics and specialty pharma company with overlapping respiratory, cardiovascular and anti-infective portfolios and similar emerging-market distribution strengths.
• Dr. Reddy's Laboratories: Indian pharma major with comparable generics portfolio across CV, GI and oncology, plus US ANDA pipeline; historic supplier of brands acquired by Torrent in 2022.
• Lupin: Indian pharma company with overlapping therapy areas (CV, diabetology, CNS, women's health) and comparable US generics presence; closely comparable business model.
• Zydus Lifesciences: Indian pharma peer with strong India generics, biosimilars and US business; co-marketing partner with Torrent for Saroglitazar Mg, making it both a peer and a commercial partner.
• Glenmark Pharmaceuticals: Indian pharma company with overlapping diabetology and chronic therapy focus; co-marketing partner for Remogliflozin in India, similar emerging-market profile.
• Aurobindo Pharma: Indian generics heavyweight with extensive US ANDA portfolio and similar broad therapeutic coverage; comparable scale and contract manufacturing exposure.
• Alkem Laboratories: Indian pharma company with strong domestic acute and chronic portfolio in similar therapeutic areas (CV, anti-infectives, GI); closely comparable India field-force-driven model.
• Mankind Pharma: Leading Indian domestic pharma company with strong field-force-driven model across chronic and acute therapies; overlapping consumer healthcare (OTC) and chronic prescription segments.

Broad incumbents

• Viatris (Mylan): Global generics incumbent with broad portfolio in the same therapy areas; competes with Torrent in US ANDAs, Europe and emerging markets and is a useful scale benchmark.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/torrentpharmain
• Facebookfacebook.com/TorrentPharmaceuticalsLimited/?fref=nf
• LinkedInlinkedin.com/company/torrent-pharmaceuticals-ltd

Compliance14 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A7 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Torrent Pharmaceuticals